Quetiapine for akutt bipolar lidelse: Systematisk oversikt og metaanalyse

Quetiapine for acute bipolar depression: a systematic review and meta-analysis

Authors
Suttajit, S. Srisurapanont, M. Maneeton, N. Maneeton, B.
Year
2014
Journal
Drug design, development & therapy
Volume
8
Pages
827-38
BACKGROUND: Precise estimated risks and benefits of quetiapine for acute bipolar depression are needed for clinical practice. OBJECTIVE: To systematically review the efficacy and the tolerability of quetiapine, either as monotherapy or combination therapy, for acute bipolar depression. METHODS: We included all randomized, controlled trials (RCTs) comparing quetiapine with other treatments, including placebo, in patients with acute bipolar depression (bipolar I or II disorder, major depressive episode). Published and unpublished RCTs were identified using the Cochrane Central Register of Controlled Trials, MEDLINE, Web of Knowledge, CINAHL, PsycINFO, the EU Clinical Trials Register database, and ClinicalTrials.gov. The primary outcome was the change scores of depression rating scales. RESULTS: Eleven RCTs (n=3,488) were included. Two of them were conducted in children and adolescents. The change in depression scores was significantly greater in the quetiapine group compared with the placebo group (mean difference, [MD] =-4.66, 95% confidence interval [CI] -5.59 to -3.73). The significant difference was observed from week 1. Compared with placebo, quetiapine had higher incidence rates of extrapyramidal side effects, sedation, somnolence, dizziness, fatigue, constipation, dry mouth, increased appetite, and weight gain but lower risks of treatment-emergent mania and headache. Quetiapine treatment was associated with significant improvement of clinical global impression, quality of life, sleep quality, anxiety, and functioning. CONCLUSION: Quetiapine monotherapy is effective for acute bipolar depression and the prevention of mania/hypomania switching. Its common adverse effects are extrapyramidal side effects, sedation, somnolence, dizziness, fatigue, constipation, dry mouth, increased appetite, and weight gain. The lower risk of headache in quetiapine-treated patients with acute bipolar depression should be further investigated. The evidence for the use of quetiapine combined with mood stabilizers in children and adolescents with acute bipolar depression is too small to support the clinical practice.

Oversett med Google Translate
-
Type of intervention

Treatment and Child Welfare Interventions

Topic

Mental Health Problems and Disorders

Emotional Problems

Bipolar Disorders

Intervention

Pharmacological Treatment

Antipsychotics

Age group

School Aged Children (6-12 years)

Adolescents (13-18 years)

Age not specified

More information
Looking for more information on this topic? Click on the links below to search PsykTestBarn and Håndboka